Belite Bio (BLTE) Share-based Compensation (2024 - 2025)

Belite Bio (BLTE) recorded quarterly Share-based Compensation of $11.7 million in Q4 2025, up 178.57% quarter-over-quarter from $4.2 million in Q4 2024, and up 178.57% on a YoY basis from $4.2 million in Q4 2024.

Belite Bio (BLTE) Share-based Compensation (2024 - 2025) Analysis & Trends

Belite Bio's Share-based Compensation history runs 2 years deep, the most recent figure standing at $11.7 million for Q4 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Share-based Compensation (Qtr)
1 Alterity Therapeutics 925,601.88 Bn 925,601.85 Bn - -
2 Belite Bio 58,560.00 Bn 58,560.00 Bn - -
3 Quantum Biopharma 17,284.41 Bn 17,284.40 Bn - -
4 Legend Biotech 2,809.00 Bn 2,808.71 Bn 242.10 Mn -
5 Evaxion A 1,334.43 Bn 1,334.42 Bn - -
6 Akari Therapeutics 1,312.27 Bn 1,312.26 Bn - 305,000.00
7 Psyence Biomedical 212.16 Bn 212.16 Bn - -
8 Vertex Pharmaceuticals 114.83 Bn 107.58 Bn 2.59 Bn 166.40 Mn
9 Abivax 91.96 Bn 91.96 Bn - 26.47 Mn
10 Regeneron Pharmaceuticals 63.43 Bn 54.67 Bn 3.31 Bn 257.40 Mn

Historic Data

Download Data
DateValue
Dec 31, 2025 11.71 Mn
Dec 31, 2025 11.71 Mn
Dec 31, 2024 4.21 Mn
Dec 31, 2024 4.21 Mn